Description
Product Usage Information
Rosiglitazone Maleate is supplied as a lyophilized powder. For a 10 mM stock, reconstitute 5 mg of powder in 1.06 mL of DMSO. Working concentrations and length of treatment can vary depending on the desired effect.
Storage
Store lyophilized at room tempertaure, desiccated. In lyophilized form, the chemical is stable for 24 months. Once in solution, store at -20ºC and use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles .
Background
Rosiglitazone Maleate is an agonist of peroxisome proliferator-activated receptor γ (PPARγ), a ligand-activated nuclear receptor preferentially expressed in adipocytes, vascular smooth muscle cells, and macrophages. Rosiglitazone Maleate mediates adipogenesis, lipid metabolism, and insulin sensitivity (1). Rosiglitazone Maleate binds both PPARγ1 and PPARγ2 isoforms with high affinity. Treatment of mesenchymal stem cells with Rosiglitazone Maleate resulted in adipocyte differentiation (2). The treatment of type 2 diabetes mellitus using Rosiglitazone Maleate is controversial as its use can lead to serious side effects, including myocardial hypertrophy and heart failure (3). Exposure of murine neuroblastoma cells and primary hippocampal neurons to Rosiglitazone Maleate protected these cells from oxidative stress. Rosiglitazone Maleate binding to PPARγ activated transcription of neurotrophic factor-α1 (NF-α1), which promoted increased expression of BCL-2 and inhibition of caspase-3 (4). Studies suggest that Rosiglitazone Maleate prevents microglial activation, promotes microglial anti-inflammatory polarization, and suppresses inflammatory cytokines in inflammation-related diseases. In a mouse model of status epilepticus, Rosiglitazone Maleate prevented microglial activation and inhibited pilocarpine-induced status epilepticus (5).
Alternate Names
5-[[4-[2-(Methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; BRL-49653C; maleate
